Status:
UNKNOWN
Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection
Lead Sponsor:
Réseau de Santé Vitalité Health Network
Collaborating Sponsors:
Janssen Inc.
Conditions:
Schizophrenia Spectrum and Other Psychotic Disorders
Eligibility:
All Genders
18-65 years
Brief Summary
The primary objective of this single-center multi-site retrospective chart review is to determine if paliperidone palmitate and/or risperidone long-acting injection can decrease the number of psychiat...
Eligibility Criteria
Inclusion
- • Patients who were initiated on either Risperidone long-acting injection or Paliperidone palmitate during an acute psychiatric admission for schizophrenia or other psychotic related disorders.
Exclusion
- Patients who had their long-acting injection stopped prior to the discharge date of their index admission.
- Patients who received a long-acting injection in the year prior to the index admission.
- Patients who had a psychiatric admission to a forensic, rehabilitation or high dependency unit during the observation period prior to or following their index admission.
Key Trial Info
Start Date :
January 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
328 Patients enrolled
Trial Details
Trial ID
NCT03390712
Start Date
January 2 2018
End Date
December 1 2018
Last Update
January 4 2018
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chaleur Regional Hospital
Bathurst, New Brunswick, Canada, E2A 4L7
2
Campbellton Regional Hospital
Campbellton, New Brunswick, Canada, E3N 3H3
3
Edmundston Regional Hospital
Edmundston, New Brunswick, Canada, E3V 4E4
4
Dr. George-L.-Dumont University Hospital Center
Moncton, New Brunswick, Canada, E1C 2Z3